Friday, May 24, 2019

Sex Differences In Immune Checkpoint Therapy

Women seem to do better than men in immune checkpoint therapy for cancer.  Studying such differences may help devise improved therapeutic approaches for all patients.  Thus - “The pooled overall survival HR was 0·72 (95% CI 0·65-0·79) in male patients treated with immune checkpoint inhibitors, compared with men treated in control groups. In women treated with immune checkpoint inhibitors, the pooled overall survival HR compared with control groups was 0·86 (95% CI 0·79-0·93). The difference in efficacy between men and women treated with immune checkpoint inhibitors was significant (p=0·0019).’

No comments:

Post a Comment